# STATE OF NEW YORK

8836

# IN ASSEMBLY

January 13, 2022

Introduced by M. of A. GOTTFRIED -- read once and referred to the Committee on Health

AN ACT to amend the public health law, in relation to newborn screening for glucose-6-phosphate dehydrogenase deficiency

**The People of the State of New York, represented in Senate and Assembly, do enact as follows:**

Section 1. Paragraph (j) of subdivision 1 of section 2500-a of the public health law, as added by a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A. 4572 and S. 4316, is amended to read as follows:

(j) Glucose-6-phosphate dehydrogenase deficiency **using a quantitative enzymatic test or other diagnostic test in cases where: the newborn infant presents with hemolytic anemia, hemolytic jaundice, or early-onset increasing neonatal jaundice, that is, jaundice (bilirubin level greater than fortieth percentile for age in hours) persisting beyond the day of birth through the week after birth; the newborn infant has been admitted to the hospital for jaundice following birth; or the biological parent of the newborn infant indicates a family, racial, or ethnic risk of glucose-6-phosphate dehydrogenase deficiency, including having significant African, Asian, Mediterranean, or Middle Eastern ancestry**.

§ 2. This act shall take effect on the same date and in the same manner as a chapter of the laws of 2021 amending the public health law relating to newborn screening for adrenoleukodystrophy and glucose-6-phosphate dehydrogenase deficiency, as proposed in legislative bills numbers A. 4572 and S. 4316, takes effect. Effective immediately, the commissioner of health shall make regulations and take other actions reasonably necessary to implement this act on that date.

EXPLANATION--Matter in *italics* (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD00136-02-2